Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability

References

• Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89:225–40.
   PubMed Web of Science ®Google Scholar
• Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73:705–13.
   PubMed Web of Science ®Google Scholar
• Dörr J, Bitsch A, Schmailzl KJ, Chan A, von Ahsen N, Hummel M, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurol. 2009;73:991–3.
   PubMed Web of Science ®Google Scholar
• Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;5:CD002127.
   PubMedGoogle Scholar
• Cree BA. 2014 multiple sclerosis therapeutic update. Neurohospitalist. 2014;4:63–5.
   PubMedGoogle Scholar
• Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust. 2008;188:26–8.
   PubMed Web of Science ®Google Scholar
• Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, van der Meer DM. Methodology of an international study of people with multiple sclerosis recruited through web 2.0 platforms: demographics, lifestyle, and disease characteristics. Neurol Res Int. 2013;2013:580596.
   PubMedGoogle Scholar
• Solari A, Filippini G, Mendozzi L, Ghezzi A, Cifani S, Barbieri E, et al. Validation of Italian multiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg Psychiatry. 1999;67:158–62.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ogata K, Katagishi M, Shimizu H, Ogawa M, Yamamura T, et al. [Validation of the Japanese-translated version multiple sclerosis quality of life-54 instrument]. Rinsho Shinkeigaku. 2004;44:417–21.
   PubMedGoogle Scholar
• Acquadro C, Lafortune L, Mear I. Quality of life in multiple sclerosis: translation in French Canadian of the MSQoL-54. Health Qual Life Outcomes. 2003;1:70.
   PubMedGoogle Scholar
• Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler. 2001;7:340–4.
   PubMed Web of Science ®Google Scholar
• Wang JL, Reimer MA, Metz LM, Patten SB. Major depression and quality of life in individuals with multiple sclerosis. Int J Psychiatry Med. 2000;30:309–17.
   PubMed Web of Science ®Google Scholar
• Tepavcevic DK, Kostic J, Basuroski ID, Stojsavljevic N, Pekmezovic T, Drulovic J. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler. 2008;14:1131–6.
   PubMed Web of Science ®Google Scholar
• Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45:251–5.
   PubMed Web of Science ®Google Scholar
• Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler. 1999;5:349.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology. 2005;65:1066–70.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology. 2006;66:1235–40.
   PubMed Web of Science ®Google Scholar
• Hadjimichael O, Vollmer T, Oleen-Burkey M. North American Research Committee on Multiple Sclerosis. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008;6:100.
   PubMed Web of Science ®Google Scholar
• Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–3.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed 2014 July 3) Obesity and overweight. Geneva: World Health Organization; 2014.
   Google Scholar
• Coyle PK. Disease-modifying agents in multiple sclerosis. Ann Indian Acad Neurol. 2009;12:273–82.
   PubMed Web of Science ®Google Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–92.
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler. 2014;20:243–52.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/nchs/fastats/obesity-overweight.htm (accessed 2014 July 3) Obesity and overweight. Georgia: CDC; 2014.
   Google Scholar
• Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol. 2009;66:513–20.
   PubMed Web of Science ®Google Scholar
• Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012;308:247–56.
   PubMed Web of Science ®Google Scholar
• Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68:145–50.
   PubMed Web of Science ®Google Scholar
• Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev. 2008;1:CD006264.
   PubMedGoogle Scholar
• Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19:S24–S40.
   PubMed Web of Science ®Google Scholar
• Taylor KL, Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, et al. Lifestyle and demographic factors and medications associated with depression risk in an international sample of people with multiple sclerosis. BMC Psychiatry. 2014;14:327.
   PubMed Web of Science ®Google Scholar
• Sheng P, Hou L, Wang X, Wang X, Huang C, Yu M, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One. 2013;8:e81802.
   PubMed Web of Science ®Google Scholar
• Weiland TJ, Jelinek GA, Marck CH, Hadgkiss EJ, van der Meer DM, Pereira NG, et al. Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis. PLoS One. 2015;10(2):e0115541.
   PubMed Web of Science ®Google Scholar
• Thelen JM, Lynch SG, Bruce AS, Hancock LM, Bruce JM. Polypharmacy in multiple sclerosis: relationship with fatigue, perceived cognition, and objective cognitive performance. J Psychosom Res. 2014;76:400–4.
   PubMed Web of Science ®Google Scholar
• Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(Suppl 5 Improving):S139–45.
   PubMedGoogle Scholar
• Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011;17(Suppl 5 Improving):S146–53.
   PubMedGoogle Scholar
• Johnson KP, Due DL. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2009;9:205–14.
   PubMedGoogle Scholar
• Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, de Sá JC, Edland A, et al. A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J Neurol. 2014;261(11):2101–11.
   PubMed Web of Science ®Google Scholar